Abstract 2052P
Background
Fluorouracil plus leucovorin, oxaliplatin and docetaxel (FLOT) is the standard of care for perioperative chemotherapy in resectable locally advanced gastric cancer (LAGC) in Europe. As a triplet combination, FLOT may be associated with increased toxicity. Therefore, it is crucial to investigate whether patients experience similar toxicities before and after surgery. This study aims to evaluate the toxicity profile of FLOT chemotherapy.
Methods
This observational, longitudinal, retrospective study included patients diagnosed with LAGC and treated with FLOT chemotherapy in a Portuguese medical oncology department between January 2018 and December 2020. Adverse events were classified according to Toxicity Grading CTC-AE version 5.0.
Results
Forty-seven patients with LAGC treated with FLOT chemotherapy were included in this study. The median age at diagnosis was 59.3 years (SD 8.1), and the majority of patients were male (n=29, 61.7%) with an ECOG PS of 0 (n=41, 87.2%). During the first four cycles of FLOT given before surgery, a total of 56 adverse events of any degree were observed, with 8 (17%) patients requiring treatment delay and 4 (8.5%) patients requiring dose reduction. In the 5th to 8th cycles given after surgery, there were 62 adverse events of any degree, with 13 (27.7%) patients requiring treatment delay and dose reduction. Notably, the toxicity profile differed between the pre and post-operative periods. In the first 4 cycles, the most common adverse events were nausea (n=16, 28.6%), emesis (n=9, 16.2%), and diarrhea (n=6, 10.7%), mostly with grade 2 toxicity. In the postoperative period, the main adverse events were neutropenia (n=23, 37.1%), nausea (n=6, 9.7%), and neuropathy (n=6, 9.7%). Grade 3 and 4 neutropenia occurred in 15 and 2 patients, respectively. Forty-two patients completed 8 cycles of FLOT.
Conclusions
The observed differences in toxicity between the pre- and postoperative periods highlight the importance of tailoring the treatment approach based on the patient's individual needs. Efforts to minimize dose reduction and chemotherapy delay should be made to maximize the effectiveness of FLOT therapy. Limitations of this study include the lack of data on long-term toxicity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06